PRM-151 for Idiopathic Pulmonary Fibrosis



PRM-151 is a recombinant human serum amyloid P/pentraxin 2 protein developed by Promedior, a biotechnology company developing therapies for fibrotic diseases using plasma-derived proteins and peptides. Also referred to as PTX2, the therapy is injected intravenously in patients and is showing promise as an effective anti-fibrotic agent which can be used to target several rare orphan diseases with unmet therapeutic needs.

Promedior is currently focusing on rare systemic fibrotic diseases and their prime targets include idiopathic pulmonary fibrosis (IPF), myelofibrosis and retinal fibrovascular diseases.

Read more about it:

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *